These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 25826792

  • 1. New molecular targets in the pathophysiology of obesity and available treatment options under investigation.
    Valsamakis G, Lois K, Kumar S, Mastorakos G.
    Clin Obes; 2014 Aug; 4(4):209-19. PubMed ID: 25826792
    [Abstract] [Full Text] [Related]

  • 2. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
    Shyh G, Cheng-Lai A.
    Cardiol Rev; 2014 Aug; 22(1):43-50. PubMed ID: 24304809
    [Abstract] [Full Text] [Related]

  • 3. Obesity medications: what does the future look like?
    Butsch WS.
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
    [Abstract] [Full Text] [Related]

  • 4. [The pharmacotherapy of obesity].
    Budai KA, Mirzahosseini A, Noszál Béla, Tóth G.
    Acta Pharm Hung; 2015 Oct; 85(1):3-17. PubMed ID: 26137782
    [Abstract] [Full Text] [Related]

  • 5. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H.
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [Abstract] [Full Text] [Related]

  • 6. Comparison table: some FDA-approved drugs for weight management.
    Med Lett Drugs Ther; 2018 Jun 04; 60(1548):e98-e100. PubMed ID: 29913464
    [No Abstract] [Full Text] [Related]

  • 7. Drug treatment of obesity in the cardiovascular patient.
    Charakida M, Tousoulis D, Finer N.
    Curr Opin Cardiol; 2013 Sep 04; 28(5):584-91. PubMed ID: 23928924
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological therapies for obesity.
    Kaplan LM.
    Gastroenterol Clin North Am; 2005 Mar 04; 34(1):91-104. PubMed ID: 15823441
    [Abstract] [Full Text] [Related]

  • 9. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
    Azebu LM.
    Food Drug Law J; 2014 Mar 04; 69(1):87-111, ii-iii. PubMed ID: 24772687
    [Abstract] [Full Text] [Related]

  • 10. New and emerging drug molecules against obesity.
    George M, Rajaram M, Shanmugam E.
    J Cardiovasc Pharmacol Ther; 2014 Jan 04; 19(1):65-76. PubMed ID: 24064009
    [Abstract] [Full Text] [Related]

  • 11. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S, Schwartz LM.
    JAMA Intern Med; 2014 Apr 04; 174(4):615-9. PubMed ID: 24515599
    [Abstract] [Full Text] [Related]

  • 12. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.
    Walter CP, Bleske BE, Dorsch MP.
    J Clin Pharm Ther; 2014 Oct 04; 39(5):475-84. PubMed ID: 24924286
    [Abstract] [Full Text] [Related]

  • 13. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Krentz AJ, Fujioka K, Hompesch M.
    Diabetes Obes Metab; 2016 Jun 04; 18(6):558-70. PubMed ID: 26936802
    [Abstract] [Full Text] [Related]

  • 14. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW, McClendon KS, Riche DM.
    Ann Pharmacother; 2013 Jun 04; 47(7-8):1007-16. PubMed ID: 23800750
    [Abstract] [Full Text] [Related]

  • 15. Update on pharmacology of obesity: benefits and risks.
    Cabrerizo García L, Ramos-Leví A, Moreno Lopera C, Rubio Herrera MA.
    Nutr Hosp; 2013 Sep 04; 28 Suppl 5():121-7. PubMed ID: 24010752
    [Abstract] [Full Text] [Related]

  • 16. Current Drug Targets in Obesity Pharmacotherapy - A Review.
    Bhat SP, Sharma A.
    Curr Drug Targets; 2017 Sep 04; 18(8):983-993. PubMed ID: 28245771
    [Abstract] [Full Text] [Related]

  • 17. Past, present and future of pharmacotherapy for obesity.
    Benaiges D, Pedro-Botet J, Flores-Le Roux JA, Climent E, Goday A.
    Clin Investig Arterioscler; 2017 Sep 04; 29(6):256-264. PubMed ID: 28935287
    [Abstract] [Full Text] [Related]

  • 18. Obesity: Current and potential pharmacotherapeutics and targets.
    Narayanaswami V, Dwoskin LP.
    Pharmacol Ther; 2017 Feb 04; 170():116-147. PubMed ID: 27773782
    [Abstract] [Full Text] [Related]

  • 19. Recent advances in the pathophysiology and pharmacological treatment of obesity.
    Chugh PK, Sharma S.
    J Clin Pharm Ther; 2012 Oct 04; 37(5):525-35. PubMed ID: 22462645
    [Abstract] [Full Text] [Related]

  • 20. Horizons in the Pharmacotherapy of Obesity.
    Arch JR.
    Curr Obes Rep; 2015 Dec 04; 4(4):451-9. PubMed ID: 26346394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.